Assessing consistent treatment effect in a multi‐regional clinical trial: a systematic review
暂无分享,去创建一个
Hui Quan | S Peter Ouyang | Yoko Tanaka | Joshua Chen | Ekopimo Ibia | Bruce Binkowitz | H. Quan | Gang Li | Joshua Chen | Gang Li | Shailendra Menjoge | B. Binkowitz | S. P. Ouyang | Yoko Tanaka | S. Menjoge | E. Ibia | Y. Tanaka
[1] Shein-Chung Chow,et al. ASSESSING SENSITIVITY AND SIMILARITY IN BRIDGING STUDIES , 2002, Journal of biopharmaceutical statistics.
[2] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[3] D. DeMets,et al. Statistical issues relating to international differences in clinical trials. , 2001, American heart journal.
[4] M H Gail,et al. A comparison of the power of two tests for qualitative interactions. , 1993, Statistics in medicine.
[5] W. G. Cochran. The combination of estimates from different experiments. , 1954 .
[6] H Wedel,et al. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. , 2001, American heart journal.
[7] R Dietz,et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. , 2000, JAMA.
[8] J. Tukey,et al. Tests for qualitative treatment-by-centre interaction using a 'pushback' procedure. , 1993, Statistics in medicine.
[9] Hiroyuki Uesaka,et al. Sample Size Allocation to Regions in a Multiregional Trial , 2009, Journal of biopharmaceutical statistics.
[10] Hui Quan,et al. Sample size considerations for Japanese patients in a multi‐regional trial based on MHLW guidance , 2009, Pharmaceutical statistics.
[11] R. Califf,et al. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. , 2000, European heart journal.
[12] J. Fleiss,et al. Analysis of data from multiclinic trials. , 1986, Controlled clinical trials.
[13] K. Swedberg,et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. , 2008, Journal of the American College of Cardiology.
[14] S. Pocock,et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems , 2002, Statistics in medicine.
[15] P. Lachenbruch,et al. Lot Consistency as an Equivalence Problem , 2004, Journal of biopharmaceutical statistics.
[16] Christy Chuang-Stein,et al. An Approach to Rationalize Partitioning Sample Size into Individual Regions in a Multiregional Trial , 2008 .
[17] James J. Chen,et al. Sample Size Requirements for Evaluation of Bridging Evidence , 2002 .
[18] A. Vickers,et al. Do certain countries produce only positive results? A systematic review of controlled trials. , 1998, Controlled clinical trials.
[19] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[20] M. Gail,et al. Testing for qualitative interactions between treatment effects and patient subsets. , 1985, Biometrics.
[21] H. White,et al. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial , 2001, The Lancet.
[22] Y. Chen,et al. Testing for Crossover of Two Hazard Functions Using Gail and Simon's Method , 2006, Journal of biopharmaceutical statistics.